Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H18N2O3 |
| Molecular Weight | 322.3578 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)CCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3
InChI
InChIKey=LGYTZKPVOAIUKX-UHFFFAOYSA-N
InChI=1S/C19H18N2O3/c1-14(22)12-13-17-18(23)20(15-8-4-2-5-9-15)21(19(17)24)16-10-6-3-7-11-16/h2-11,17H,12-13H2,1H3
| Molecular Formula | C19H18N2O3 |
| Molecular Weight | 322.3578 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf
Sources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf
Kebuzone is a cyclooxygenase inhibitor that was used for the treatment of different inflammatory conditions such as thrombophlebitis and rheumatoid arthritis. The current marketing status of the drug is unknown and supposed to be discontinued.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094253 Sources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | KETAZON Approved UseInflammatory and degenerative inflammatory activated forms of rheumatism; rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, neuritis and neuralgia as cervical syndrome, lumbago, sciatica, gout; rheumatism; painful inflammation after injury or surgery; thrombophlebitis. |
|||
| Palliative | KETAZON Approved UseInflammatory and degenerative inflammatory activated forms of rheumatism; rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, neuritis and neuralgia as cervical syndrome, lumbago, sciatica, gout; rheumatism; painful inflammation after injury or surgery; thrombophlebitis. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. | 2001-06-02 |
|
| [Intrahepatic cholestasis following ketazone successfully treated using the enzyme inductor phenobarbital]. | 1978-04 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.pharmazie.com/graphic/A/24/0-13524.pdf
1 (250 mg) to 2 dragees 3 times daily
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:32:39 GMT 2025
by
admin
on
Mon Mar 31 18:32:39 GMT 2025
|
| Record UNII |
4VD83UL6Y6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
M01AA06
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
||
|
WHO-VATC |
QM01AA06
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
||
|
NCI_THESAURUS |
C257
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2444
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
Kebuzone
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
DB08940
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
4VD83UL6Y6
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
28198
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | RxNorm | ||
|
31749
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
212-715-7
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
SUB08363MIG
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107720
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
100000082866
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
C79126
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
3824
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
DTXSID00234500
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
C100280
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
m6606
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
853-34-9
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY | |||
|
1522
Created by
admin on Mon Mar 31 18:32:40 GMT 2025 , Edited by admin on Mon Mar 31 18:32:40 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |